Single-agent erlotinib was active and well tolerated in NSCLC patients with BM. Further studies are warranted.

No abstract

Small cell lung cancer (SCLC) extensive stage (ES) in Spain: Efficacy of treatments, data from the thoracic tumours registry (TTR study)

No abstract

hospitals in England, 60 took part in this spotlight audit of which 19 had on-site EGFR testing: 1,157 individual patient records were uploaded on to the portal; 512 (44%) patients were female, 353 (31%) were under the age of 65 and 758 patients (66%) had adenocarcinoma. Common methods of tissue acquisition were percutaneous lung or lymph node biopsy (31%), endobronchial ultrasound (EBUS) (24%) and from pleural fluid or pleural biopsy (11%). In a multivariate analysis, patients undergoing pleural procedures as an initial investigation were twice as likely to require a second procedure for molecular analysis as patients undergoing EBUS. Of the 758 patients with an adenocarcinoma subtype, 701 (92%) underwent EGFR testing. Testing failed in only 3% of patients and 71 (9.4%) had a sensitising EGFR mutation. The median time from biopsy to EGFR result was 18 days (interquartile range 14e23) with a median of 9 days from arrival in the molecular lab to EGFR result. In patients with a sensitising EGFR mutation, 53 (75%) received a first-line TKI, 3 (4%) received first-line chemotherapy, 1 (1%) patient received immunotherapy and treatment was unknown in 14 (20%). The median survival of patients with an EGFR mutation was 19 months Conclusion: In this study, samples acquired by pleural procedures were less suitable for EGFR testing. Comprehensive EGFR testing has been successfully implemented on a national scale using regional centres. Further quality improvement measures are required to reduce time to EGFR result.